Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome
- PMID: 24929631
- DOI: 10.1016/j.jiac.2014.05.001
Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome
Abstract
By the age of two years, almost all infants are infected with the Respiratory syncytial virus (RSV). One of the main causes of hospitalizations for bronchiolitis and pneumonia at this age is RSV infection. In addition to well-known risks for severe RSV disease, such as prematurity, bronchopulmonary dysplasia and congenital heart disease, immunodeficiencies, chromosomal abnormalities such as Down's syndrome or neuromuscular diseases have also been identified as risks. While the medical needs for RSV prevention in these risk groups are high, clinical evidence to support this is limited. Palivizumab was recently approved in Japan for prophylaxis in children with immunodeficiency or Down's syndrome. A clinical guidance protocol for the prevention of RSV infection using Palivizumab in these risk groups is provided here on the basis of a review of the available literature and on expert opinion. Thus, the present article reviews the published literature related to RSV infections in infants and children with immunodeficiencies or Down's syndrome in order to outline the risks, pathology and physiology of severe RSV disease in these patient groups. The purpose of this article is to facilitate understanding of the medical scientific bases for the clinical guidance.
Keywords: Additional indications; Down's syndrome; Immunodeficiency; Palivizumab; Respiratory syncytial virus.
Copyright © 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.Pediatrics. 2014 Aug;134(2):e620-38. doi: 10.1542/peds.2014-1666. Pediatrics. 2014. PMID: 25070304
-
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665. Pediatrics. 2014. PMID: 25070315
-
Down's syndrome is a risk factor for severe lower respiratory tract infection due to respiratory syncytial virus.Acta Paediatr. 2016 Nov;105(11):e531-e535. doi: 10.1111/apa.13552. Acta Paediatr. 2016. PMID: 27537430
-
Respiratory syncytial virus disease: update on treatment and prevention.Expert Rev Anti Infect Ther. 2011 Jan;9(1):27-32. doi: 10.1586/eri.10.140. Expert Rev Anti Infect Ther. 2011. PMID: 21171875 Review.
-
New strategies for control of respiratory syncytial virus infection.Curr Opin Infect Dis. 2008 Dec;21(6):639-43. doi: 10.1097/QCO.0b013e3283184245. Curr Opin Infect Dis. 2008. PMID: 18978532 Review.
Cited by
-
Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial.Lancet Reg Health West Pac. 2023 Jul 26;39:100847. doi: 10.1016/j.lanwpc.2023.100847. eCollection 2023 Oct. Lancet Reg Health West Pac. 2023. PMID: 37554997 Free PMC article.
-
Clinical characteristics of hospitalized term and preterm infants with community-acquired viral pneumonia.BMC Pediatr. 2022 Jul 27;22(1):452. doi: 10.1186/s12887-022-03508-7. BMC Pediatr. 2022. PMID: 35897053 Free PMC article.
-
Efficacy and safety of interferon on neonates with respiratory syncytial virus pneumonia.Exp Ther Med. 2020 Dec;20(6):220. doi: 10.3892/etm.2020.9350. Epub 2020 Oct 15. Exp Ther Med. 2020. PMID: 33193835 Free PMC article.
-
Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series.Hum Vaccin Immunother. 2021 Apr 3;17(4):1235-1238. doi: 10.1080/21645515.2020.1809265. Epub 2020 Sep 22. Hum Vaccin Immunother. 2021. PMID: 32961094 Free PMC article.
-
New therapies for acute RSV infections: where are we?Eur J Pediatr. 2019 Feb;178(2):131-138. doi: 10.1007/s00431-018-03310-7. Epub 2019 Jan 4. Eur J Pediatr. 2019. PMID: 30610420 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical